Can you take Testosterone (TRT / supraphysiological) and HGH (recombinant human growth hormone) together?

Read Off Label doesn't make stack recommendations — see the disclaimer. Both compounds have individual mechanism, dose, and risk profiles documented on their respective pages; combining them is a clinical question that depends on the goal, indication, and other context.

Rankings / Comparisons

Testosterone (TRT / supraphysiological) vs HGH (recombinant human growth hormone)

The two pillars of the off-label performance corner — anabolic effect, risk profile, and legal exposure compared.

Reviewed by Read Off Label · How we grade

Bottom line

On the composite score, Testosterone (TRT / supraphysiological) (B, 6.8/10) edges out HGH (recombinant human growth hormone) (C-, 4.2/10) — but the right pick depends on the specific outcome you're optimising for.

Testosterone (TRT / supraphysiological)

B 6.8/10

Evidence: Strong (muscle, bone, sexual function in hypogonadism); Strong (muscle in eugonadal at supraphysiological doses — Bhasin 1996) (8/10)
Benefit: Strong (supraphys); Med (TRT) (8/10)
Risk: Med (TRT); High (supraphysiological — erythrocytosis/HCT>54, HPG suppression/infertility, gynecomastia, acne, sleep apnea, prostate/BPH; CV risk NOT increased in TRT per TRAVERSE but unclear at supraphysiological doses) (5/10 safety)
Legality: Rx for hypogonadism (Schedule III US as anabolic steroid); illicit supraphysiological use illegal
Dose: TRT: testosterone cypionate/enanthate 100-200 mg/week IM/subQ, or daily gel; supraphysiological cycles 300-1000+ mg/week
Class: Anabolic
Last reviewed: Jun 8, 2026

Read Off Label grades Testosterone (TRT / supraphysiological) as B (6.8/10) based on strong evidence, strong benefit magnitude, and a med-risk safety profile.

Typical use: TRT: testosterone cypionate/enanthate 100-200 mg/week IM/subQ, or daily gel; supraphysiological cycles 300-1000+ mg/week — Rx for hypogonadism (Schedule III US as anabolic steroid); illicit supraphysiological use illegal.

What it is

TRAVERSE 2023 (n=5246, high CV risk hypogonadal men) — TRT non-inferior to placebo for MACE; no prostate cancer increase; small increases in atrial fibrillation, VTE, fractures, acute kidney injury. Reduced progression to diabetes. FDA February 2025 label change: REMOVED boxed warning for major adverse cardiovascular events; ADDED class-wide warning for blood pressure increases (per ambulatory BP monitoring data). Bhasin 1996 NEJM remains definitive demonstration of dose-dependent muscle gain in healthy men. Yeap 2026 J Clin Endocrinol Metab review: nonlinear association of low testosterone with all-cause mortality below ~213 ng/dL.

Mechanism

Prototypical androgen receptor agonist; increases muscle protein synthesis, satellite cell activation, erythropoiesis, bone density; aromatizes to estradiol (necessary for bone, libido, lipids)

Full Testosterone (TRT / supraphysiological) review →

HGH (recombinant human growth hormone)

C- 4.2/10

Evidence: Weak-Moderate (anti-aging claims — Rudman 1990 reanalyses show muscle gain but no functional benefit, increased side effects); Strong (deficiency indications: pediatric GHD, adult GHD, Turner, wasting) (4.5/10)
Benefit: Med (5/10)
Risk: Med-High (carpal tunnel, edema, insulin resistance / overt diabetes, arthralgia; tumor growth promotion concern; cardiomegaly at high chronic doses; expensive — $800-1500/month) (3.5/10 safety)
Legality: Rx for approved indications; off-label/illicit for anti-aging/performance illegal in US (Anti-Drug Abuse Act of 1988 specifically criminalizes non-indicated HGH)
Dose: Clinical: 0.005-0.03 mg/kg/day subQ; anti-aging/illicit: 2-4 IU/day
Class: Anabolic
Last reviewed: Jun 8, 2026

Read Off Label grades HGH (recombinant human growth hormone) as C- (4.2/10) based on weak-moderate evidence, med benefit magnitude, and a med-high-risk safety profile.

Rudman 1990 NEJM revived anti-aging interest — but followups show muscle gain with no functional improvement and high side effect burden.

Typical use: Clinical: 0. — Rx for approved indications; off-label/illicit for anti-aging/performance illegal in US.

What it is

Rudman 1990 NEJM revived anti-aging interest — but followups show muscle gain with no functional improvement and high side effect burden. Liu 2007 Annals systematic review: in healthy older adults, HGH increases lean mass modestly but increases adverse events without improving performance. Expensive; counterfeits widespread in illicit market.

Mechanism

Exogenous somatotropin; binds GHR; raises IGF-1; lipolytic; promotes collagen, cartilage, connective tissue; muscle anabolism modest on its own but synergistic with androgens

Full HGH (recombinant human growth hormone) review →

Common questions

Which is better, Testosterone (TRT / supraphysiological) or HGH (recombinant human growth hormone)?: On the composite score, Testosterone (TRT / supraphysiological) (B, 6.8/10) edges out HGH (recombinant human growth hormone) (C-, 4.2/10) — but the right pick depends on the specific outcome you're optimising for.
What's the difference between Testosterone (TRT / supraphysiological) and HGH (recombinant human growth hormone)?: The two pillars of the off-label performance corner — anabolic effect, risk profile, and legal exposure compared.
Can you take Testosterone (TRT / supraphysiological) and HGH (recombinant human growth hormone) together?: Read Off Label doesn't make stack recommendations — see the disclaimer. Both compounds have individual mechanism, dose, and risk profiles documented on their respective pages; combining them is a clinical question that depends on the goal, indication, and other context.

This is an independent synthesis of published research by a non-clinician. Comparison-page verdicts use the composite Read Off Label score as a tiebreaker, but the right pick for any given person depends on indication, context, and clinician input. See the full disclaimer and methodology.